NT pro- B-type Natriuretic Peptide in the Small Ventricular Septal Defect in Children

Rahmat Budi Kuswiyanto1*, Putria Apandi1†, Dany Hilmanto1*, Muhammad Hasan Bashari1*, Sri Rahayuningsih1*  
1Department of Pediatric and Child Health, Hasan Sadikin Hospital, Universitas Padjajaran, Indonesia; 2Department of Pharmacology and Therapy Faculty of Medicine Universitas Padjajaran, Indonesia

Abstract

BACKGROUND: Brain natriuretic peptide is a cardiac hormone secreted from the left ventricular myocardium due to ventricular expansion and volume overload. A recent study shows that small ventricular septal defect (VSD) will have risk of ventricular dysfunction in adulthood. Another complications such as endocarditis, congestive heart failure, aortic regurgitation, arrhythmia also we should be aware. Evaluations of the plasma B-type natriuretic peptide level (NT pro BNP) are currently being considered as methods to identify the possible presence of ventricular dilation in small VSD.

AIM: The objective of the study is to evaluate the change in plasma BNP after transcatheter closure of VSD.

METHODS: A pretest-posttest design was conducted on VSD patients before and after transcatheter closure. Plasma BNP levels were measured before and 30 days after the transcatheter closure of VSD.

RESULTS: A total of 32 peri membranous VSD (pmVSD) patients were included in this study with 62.5 % female patients (n = 20) and 37.5 % male patients (n = 12). A significant decrease was observed in the median NT pro BNP level when the level before closure of 1.08 (0.74–3.47) ng/ml was compared to the level after closure of 0.91 (0.68–2.07) ng/ml (p < 0.05).

CONCLUSION: Significant decreases in NT pro BNP level are seen in small VSD patients 30 days after transcatheter closure. Patients with small pmVSD are generally considered to need occlusion for their childhood defect.

Introduction

Brain natriuretic peptide is a cardiac hormone secreted from the left ventricular myocardium due to ventricular expansion and volume overload. It is synthesized as a preprohormone containing 108 amino acids processing releases the biologically active-32 amino acids peptide and an N-terminal pro-brain natriuretic peptide [1].

A recent study shows that small ventricular septal defect (VSD) will impact adulthood, the complications such as endocarditis, congestive heart failure, aortic regurgitation, arrhythmia, and ventricular dysfunction [2], [3], [4]. Nevertheless, data on plasma B-type natriuretic peptide (BNP) are still scarce, particularly in small peri membranous VSD (pmVSD). Thus, the purpose of this study was to determine plasma BNP levels in children before and after transcatheter closure of a small pmVSD.

Patients and Methods

The Medical Research Ethics Committee approved this ethical clearance of Dr. Hasan Sadikin General Hospital Bandung, Indonesia. A pretest-posttest design was conducted on pmVSD patients before and after transcathater closure of pmVSD. The inclusion criteria for the subject were patients with small pmVSD as measured using echocardiography and angiography, those under 18 years old, and QP/QS <1.5. Small pmVSD in this study was defined as a VSD with a size of less than one-third of the aorta diameter annulus. Prior to the procedure, echocardiography was done to evaluate LV dimension using m-mode echocardiography. One month after the procedure, we also observed the valve regurgitation, particularly aortic regurgitation, device position, and residual shunt after the procedure. Echocardiography was performed using Philips epic 7 (Philips North American Corporation USA) echocardiography machine for 2D imaging. Thirty-two subjects participated in this study (minimum required sample size = 30).
Clinical assessment

All children underwent a clinical examination, including a complete cardiac examination. The severity of HF was determined using the Modified Ross's Clinical Score for heart failure diagnosis. This score classified patients into No cardiac heart failure (CHF) = 0–2 points, mild CHF 3–6 points, moderate CHF 7–9 points, and severe CHF 10–12 points [5].

Echocardiography assessment before percutaneous closure

We assist VSD carefully before the procedure. VSD assessment was performed, which included: Site of VSD, size of the VSD from both sides of defect, and abnormality of the valve.

Amino-terminal pro-brain natriuretic peptide measurements

All blood samples for NT-pro BNP measurement were collected before the VSD closure procedure and 1 month after the procedure. Samples were collected in a tube and centrifuged for 10 min at 3000 rpm. Serum was extracted and stores in –80°C until the analysis day. ELISA techniques determined the plasma concentration of NT-pro BNP in the plasma. (Elabsience Biotechnology Inc).

Follow-up

After VSD device closure, all patients received tablet aspirin at a dose of 3–5 mg/kg/day for 6 months. On the day of discharge and 1 month after the procedure, a clinical examination, electrocardiography monitoring, and transthoracic echocardiography were conducted to determine the left ventricular end-diastolic diameter (LVEDD). One month after the procedure, pediatric cardiologists who are blind to the procedure will do transthoracic echocardiography, quantify m-mode, and evaluate valve regurgitation, device location, and residual shunt.

Statistical analysis

Statistical analysis was performed using the Statistical Package for Social Sciences for windows version 18.0. Analysis was performed using descriptive statistics, and all data were expressed as mean ± standard deviation and % ratio. Numeric data with normal distribution were analyzed by paired t-test, and non-normal distribution data were analyzed by Wilcoxon test. p < 0.05 was considered statistically significant.

Results

This study was conducted during the study period of July 2019 to December 2019. Percutaneous closure of VSDs was successfully performed in all patients. Subjects comprised 12 males and 20 females. All patients were asymptomatic, no symptoms occurred, and no one had a recurrent respiratory infection. Aortic regurgitation and prolapse of the right coronary cusp of the aorta were observed before the procedure in 6% and 12% of patients, respectively. After the procedure, the trivial aortic regurgitation was seen in 3 patients (9.3 %). No death or urgent cardiac surgery complication was seen during the study period, and no device embolization occurred. Furthermore, no atrioventricular block was observed on electrocardiography evaluation. One patient developed sinus bradycardia but normal in systolic and diastolic functions. Intra-device mild residual shunt remained in 12 patients. No hematoma occurred. There was no death, endocarditis, or device-related complication was seen during the follow-up.

The characteristic data is shown in Table 1. Almost all children who include in this study has normal weight and no heart failure observe. Table 2 shows that the heart function before and after intervention had no significance difference, but the NTproBNP and heart dimension show significance decrement.

Discussion

There are controversies about treatment for small VSD. Small, restrictive, and isolated VSDs with a small left to right shunt rarely develop pulmonary hypertension and have an excellent long-term prognosis [6], [7]. However, there is evidence of a long-term prognosis of LV dysfunction in adulthood, which may be a rationale for small VSD closure in childhood [8]. We hypothesized that there might be a chronical volume overload due to LVEDD dilatation, although the size of the VSD is small. Left ventricular dilatation is one of the complications of left ventricular volume overload caused by VSD.

Recent studies have shown that serum BNP level increases during different types of hemodynamic overload of the heart, including in VSD [9], [10]. The main stimulus for increased BNP and NT pro BNP synthesis and secretion is the myocardial wall stress. BNP and NT pro BNP are cardiac hormones produced from the myocardium of the left ventricle in response to ventricular pressure and/or volume overload [11], [12], [13]. However, the cut-off values of NT-pro BNP reference level in children have not been fully evaluated, a previous research conducted by Kim et al. show that even in normal children without cardiac disease the level
of NT pro BNP were in range 6–35.000 pg/ml, and in this study also show that in cardiac patient show higher level of NT-pro BNP compare with children without cardiac disease [14]. In this study, the NT pro-BNP levels 1 day before and 30 days after transcatheter closure of small pmVSD were evaluated, and a significant decrease of NT pro-BNP 30 days after small pmVSD closure by transcatheter was observed. This shows that even in small pmVSD, LV volume overload should be considered because it may lead to a hyervolumic situation. Hence, closing small pmVSD is considered advantageous.

Table 2: Heart dimension, function, and NT pro BNP level before and after the procedure

<table>
<thead>
<tr>
<th>Variable</th>
<th>n=32</th>
<th>Follow-up</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Month 0</td>
<td>Month 1</td>
</tr>
<tr>
<td>LVENDD (mm)</td>
<td>32</td>
<td>39.1±6.5</td>
<td>37.5±5.8</td>
</tr>
<tr>
<td>LVESD (mm)</td>
<td>32</td>
<td>24.7±4.0</td>
<td>24.0±4.1</td>
</tr>
<tr>
<td>NT pro-BNP (ng/ml)</td>
<td>32</td>
<td>0.08(0.74–3.47)</td>
<td>0.09(0.68–2.07)</td>
</tr>
<tr>
<td>MPI-LV</td>
<td>32</td>
<td>0.36±0.06</td>
<td>0.33±0.08</td>
</tr>
<tr>
<td>LV mass index</td>
<td>32</td>
<td>83.2±29.4</td>
<td>85.8±20.5</td>
</tr>
<tr>
<td>EF (%)</td>
<td>32</td>
<td>66.8±6.0</td>
<td>64.7±5.5</td>
</tr>
<tr>
<td>FS (%)</td>
<td>32</td>
<td>36.4±4.5</td>
<td>37.1±4.4</td>
</tr>
<tr>
<td>Distant to aortic valve from angiography (mm)</td>
<td>32</td>
<td>1.30±0.24</td>
<td>1.25±0.23</td>
</tr>
</tbody>
</table>

Table 1: Subject characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td>8.6±4.2</td>
<td></td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td>Boy</td>
<td>12 (37.5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Girl</td>
<td>20 (62.5)</td>
<td></td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>Mean (Min–Max)</td>
<td>22.0 (10.0–45.0)</td>
<td></td>
</tr>
<tr>
<td>BMI/IM</td>
<td>Mean (Min–Max)</td>
<td>122 (75–160)</td>
<td></td>
</tr>
<tr>
<td>Nor width (~2–2 SD)</td>
<td>Median (Min–Max)</td>
<td>31 (94.0)</td>
<td></td>
</tr>
<tr>
<td>Skinny (~&lt;2SD)</td>
<td>Mean</td>
<td>1 (3.0)</td>
<td></td>
</tr>
<tr>
<td>Very thin (~&lt;3SD)</td>
<td>Mean</td>
<td>1 (3.0)</td>
<td></td>
</tr>
<tr>
<td>Ross score, n (%)</td>
<td>0</td>
<td>31 (94.0)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>1 (3.0)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2 (0.97–7.78)</td>
<td></td>
</tr>
<tr>
<td>Qp/Qs</td>
<td>Mean ± SD</td>
<td>1.18 ± 0.14</td>
<td></td>
</tr>
<tr>
<td>Fluoro time (mm: ss)</td>
<td>Median (Min–Max)</td>
<td>24:49 (09:33–72:05)</td>
<td></td>
</tr>
<tr>
<td>Procedure time (h: min: mm)</td>
<td>Mean (Min–Max)</td>
<td>01:20 (00:50–02:50)</td>
<td></td>
</tr>
<tr>
<td>Defect size at RV from TTE (mm)</td>
<td>Mean</td>
<td>3.39 ± 0.71</td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>2.80 ± 1.24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA/Ao</td>
<td>Mean ± SD</td>
<td>1.30 ± 0.24</td>
<td></td>
</tr>
<tr>
<td>RV: Right ventricle, LV: Left ventricle, TTE: Transthoracic echocardiography.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In this prospective follow-up study, the impacts of small pmVSD closure to LEVDD and NT pro BNP level 1 month after the procedure were evaluated. Small pmVSD is not usually seen with heart failure. In a cohort of 124 infants, the incidence of spontaneous closure was found to increase to 67% at 5 years of age [15]. Another study by Miyake et al. in Japan showed that spontaneous closure of pmVSD may occur at 6 years old or school age [16]. At present, there is no standard treatment for small VSDs [17]. There was no significant difference in heart function as measured by ejection fraction and FS, which is in line with the literature stating that systolic impairment typically occurs late [18], [19].

The findings of this study indicated that 1 month following percutaneous transcatheter closure of pmVSD, the LEVDD improved. This result differs from the study conducted by Ali et al. in Cairo that showed an insignificant decline in both LEVDD and left ventricular end-systolic diameter (LVESD) after 3 months of VSD closure [6]. The improvement of LEVDD after pmVSD closure might be due to the size of VSD. The size of pmVSD in this research was small VSD, different from the study conducted by Ali et al. which the size of VSDs was moderate [6]. Other complications observed were dysfunction of the left ventricle, arrhythmias, endocarditis, aortic regurgitation, and aortic valve prolapse [20], [21]. Nevertheless, this study has a limitation because it did not represent a total population. The study was only performed in two hospitals using different types of devices to close VSD, which may cause bias.

In the current study, there was no change in left ventricular ejection fraction (LVEF) after transcatheter closure, and this result was similar with Pawelec-Mojtalik et al. and Ali et al., who reported that the systolic function was not changed after VSD closure. This can be explained by the fact that patients who undergo VSD transcatheter closure mostly have small-sized restrictive defects, so the LVEF changes are subtle [6], [22].

Conclusion

Lower serum NT pro-BNP levels in small pmVSD may indicate that LV volume excess may occur, resulting in lung volume overload and later LV dysfunction. This finding provides a rationale for considering the closure of small pmVSDs in children.

References

PMid:31659511

PMid:8425323

PMid:26844920

PMid:22622940

PMid:12828576

PMid:28070239

PMid:28070239

PMid:16698841

PMid:32102709


PMid:19261109

PMid:23886608

PMid:14726034

PMid:22371767

PMid:20298987

PMid:11897452